Search Results
Found 10 results
510(k) Data Aggregation
(90 days)
The Atellica™ IM Ferritin (Fer) assay is for in vitro diagnostic use in the quantitative determination of ferritin in human serum and plasma (EDTA and lithium heparin) using the Atellica™ IM Analyzer. This assay can be used as an aid in the diagnosis of iron deficiency anemia and iron overload.
The Atellica Ferritin Assay kit includes the following components: Lite Reagent: 5.0 mL/reagent pack. Contains Goat polyclonal anti-ferritin antibody (~0.64 µg/mL) labeled with acridinium ester in HEPES buffer; protein stabilizers; sodium azide (
Here's a breakdown of the acceptance criteria and study details for the Atellica IM Ferritin Assay, based on the provided document:
Acceptance Criteria and Reported Device Performance
Criteria | Acceptance Criteria | Reported Device Performance |
---|---|---|
Precision | CLSI EP05-A3 guidelines (Evaluation of Precision Performance of Quantitative Measurement Methods) | Repeatability (Within-run): CV ranges from 1.2% to 3.5% for samples (4.2 ng/mL to 1453.6 ng/mL) and 1.2% to 1.6% for controls (51.8 ng/mL to 374.0 ng/mL). |
Within-Lab (Total Imprecision): CV ranges from 4.0% to 7.2% for samples and 4.5% to 5.5% for controls. | ||
Linearity/Assay Reportable Range | CLSI EP06-A (linearity of Quantitative Measurement Procedures). Implied: Acceptable percentage difference between observed and predicted values. | The linearity data supports an analytical measuring range of 0.9 - 1650 ng/mL. |
Predicted % Difference (Y-Ŷ)/Ŷ*100: values ranged from -8.88% to 9.47% (excluding the lowest observed value of 0.20 ng/mL which was |
Ask a specific question about this device
The ADVIA Centaur® Insulin (IRI) Master Curve Material (MCM) is for in vitro diagnostic use in the verification of calibration and reportable range of the ADVIA Centaur® Insuin assay.
The ADVIA Centaur® Insulin (IRI) Calibrator is for in vitro diagnostic use in calibrating the ADVIA Centaur® systems Insulin assays.
ADVIA Centaur® Insulin (IRI) Master Curve Material is a set of ten vials of material containing various levels of insulin in buffered saline with casein, potassium thiocyanate (3.89%), sodium azide (
The provided text describes modifications to the "ADVIA Centaur® Insulin (IRI) Master Curve Material (MCM)" and "ADVIA Centaur® Insulin (IRI) Calibrator" and outlines the studies conducted to demonstrate their substantial equivalence to predicate devices.
Here's an analysis of the acceptance criteria and the study information, extracting what is available:
1. Table of Acceptance Criteria and Reported Device Performance:
The document doesn't explicitly state quantitative acceptance criteria in a table format with corresponding performance metrics for the modified devices. Instead, it states that "Verification testing was conducted and results show that the modified devices meet pre-determined acceptance criteria." and that a "method comparison study demonstrates that human clinical sample results are equivalent with both calibrators (modified and unmodified)."
However, based on the context, the implicit acceptance criteria and reported performance would be:
Acceptance Criteria Category | Implicit Acceptance Criteria (based on "same" characteristics and equivalence claims) | Reported Device Performance (based on "same" characteristics and equivalence claims) |
---|---|---|
ADVIA Centaur® Insulin (IRI) Master Curve Material (MCM) | ||
Intended Use | Same as predicate | Same as predicate |
Instrument | Same as predicate (ADVIA Centaur Systems) | Same as predicate (ADVIA Centaur Systems) |
Form | Same as predicate (Liquid) | Same as predicate (Liquid) |
Matrix | Same as predicate (Buffered saline with casein, potassium thiocyanate, sodium azide and preservatives) | Same as predicate (Buffered saline with casein, potassium thiocyanate, sodium azide and preservatives) |
Number of Levels | Same as predicate (10) | Same as predicate (10) |
Target Concentrations | Same as predicate (0.0, 2.5, 4.5, 10.0, 20.0, 39.0, 79.0, 158, 225, 330 mU/L) | Same as predicate (0.0, 2.5, 4.5, 10.0, 20.0, 39.0, 79.0, 158, 225, 330 mU/L) |
Fill Volume | Same as predicate (1.0 mL) | Same as predicate (1.0 mL) |
Shelf Life/Stability | Same as predicate (12 months at 2-8 degrees C) | Same as predicate (12 months at 2-8 degrees C) |
On board Stability | Same as predicate (8 hours on board) | Same as predicate (8 hours on board) |
ADVIA Centaur® Insulin (IRI) Calibrator | ||
Intended Use | Same as predicate | Same as predicate |
Instrument | Same as predicate (ADVIA Centaur Systems) | Same as predicate (ADVIA Centaur Systems) |
Form | Same as predicate (Liquid) | Same as predicate (Liquid) |
Matrix | Same as predicate (Buffered saline with casein, potassium thiocyanate, sodium azide and preservatives) | Same as predicate (Buffered saline with casein, potassium thiocyanate, sodium azide and preservatives) |
Number of Levels | Same as predicate (2) | Same as predicate (2) |
Target Concentrations | Same as predicate (Low: |
Ask a specific question about this device
(205 days)
The ADVIA Centaur® Follicle Stimulating Hormone (FSH) Master Curve Material is for in vitro diagnostic use in the verification of calibration and reportable range of the ADVIA Centaur FSH assay.
The ADVIA Centaur® Free thyroxine (FT4) Master Curve Material is for in vitro diagnostic use in the verification of calibration and reportable range of the ADVIA Centaur FT4 assay.
The ADVIA Centaur® Thyroxine (T4) Master Curve Material is for in vitro diagnostic use in the verification of calibration and reportable range of the ADVIA Centaur T4 assay.
The ADVIA Centaur® Triiodothyronine (T3) Master Curve Material is for in vitro diagnostic use in the verification of calibration and reportable range of the ADVIA Centaur T3 assay.
ADVIA Centaur® FSH Master Curve Material is an in vitro diagnostic product containing various levels of follicle stimulating hormone spiked in lyophilized equine serum with sodium azide (0.1% after reconstitution) and preservatives. Each set contains eight levels (MCM1–8); with a reconstituted volume of 1.0 mL/vial per level. MCM1contains no analyte. The MCMs assigned values are lot-specific of target values: 0.00, 1.50, 4.50, 12.0, 30.0, 62.5, 130, 225 mIU/mL.
ADVIA Centaur® FT4 Master Curve Material is an in vitro diagnostic product containing various levels of thyroxine in human plasma with sodium azide. Each set contains seven levels; with a reconstituted volume of 1.0 mL/vial per level. MCM1 contains no analyte. The FT4 MCMs assigned values are lot-specific of target values: 0.00, 2.00, 5.00, 10.0, 15.0, 22.0, and 35.0 µg/dL which corresponds to FT4 values of 0.00, 0.42, 0.80, 1.70, 3.0, 5.6, and 13.5 ng/dL.
ADVIA Centaur® T4 Master Curve Material is an in vitro diagnostic product containing various levels of levothyroxine in human plasma with sodium azide and preservatives. Each set contains six levels; with a reconstituted volume of 1.0 mL/vial per level. MCM1 contains no analyte. The T4 MCMs assigned values are lot-specific of target values: 0.00, 2.50, 5.00, 10.0, 15.0. and 35.0 µg/dL.
ADVIA Centaur® T3 Master Curve Material is an in vitro diagnostic product containing various levels of liothyronine in human plasma with sodium azide and preservatives. Each se contains seven levels; with a reconstituted volume of 1.0 mL/vial per level. MCM1 contains no analyte. The T3 MCMs assigned values are lot-specific of target values: 0.00, 0.42, 0.69, 1.11, 1.65, 3.87, and 7.00 ng/mL.
The provided document describes the Siemens Healthcare Diagnostics ADVIA Centaur® Master Curve Materials (MCM) for Follicle Stimulating Hormone (FSH), Free Thyroxine (FT4), Thyroxine (T4), and Triiodothyronine (T3). These devices are quality control materials used for verification of calibration and reportable ranges of their respective ADVIA Centaur assays. The information is presented as a 510(k) Summary, which focuses on demonstrating substantial equivalence to predicate devices, rather than a detailed report of a clinical study for device performance against specific patient outcomes or diagnostic accuracy.
Here's a breakdown of the requested information based on the provided text, with an emphasis on its applicability to in vitro diagnostic quality control materials rather than typical diagnostic imaging AI studies, which often involve human readers and expert consensus.
1. Table of Acceptance Criteria and Reported Device Performance
The acceptance criteria for these devices are primarily related to stability (shelf-life, open vial, and on-board stability) and value assignment. The reported performance indicates that these criteria were met.
ADVIA Centaur® FSH Master Curve Material
Acceptance Criteria Category | Specific Acceptance Criteria | Reported Device Performance |
---|---|---|
Stability | ||
Real Time/Shelf Life (Unopened) | The dose recovery for MCM1 (analyte-free) and the % dose recoveries for MCM2-8 met the sponsor's required acceptance criteria. | Current testing meets acceptance criteria up to the 7 months' time point, supporting a 6-month shelf-life claim (storage unopened at 2-8°C). Real-time studies are ongoing. |
In-Use Open Vial (Reconstituted) | The dose recovery for MCM1 (analyte-free) and the % dose recoveries for MCM2-8 met the sponsor's required acceptance criteria. | Acceptance criteria for open vial (reconstituted) stability study were met up to the 29 days' time point, supporting an open vial claim of 28 days (when properly stored at 2-8°C). |
On-Board Stability | The dose recovery for MCM1 (analyte-free) and the % dose recoveries for MCM2-8 met the sponsor's required acceptance criteria. | On-board stability study met acceptance criteria at the 5 hours' time point, supporting an on-board stability claim for 4 hours. |
Value Assignment | The new MCM doses must fall within the final value assignment specification for FSH MCMs. The mean MCM doses of the new MCM lot manufactured must fall within the customer range specifications. MCM1 must measure at or below the FSH assay sensitivity limit. | The document states MCMs are value assigned using assigned reference calibrators and MCMs, and that MCMs are manufactured using qualified materials and measurement procedures. Performance verification runs (6 replicates per level) are conducted to ensure mean MCM doses fall within customer range specifications. No specific values or a pass/fail statement for a particular lot is provided, but implies acceptance criteria were met as part of the overall substantial equivalence. |
Expected Values | Lot-specific assigned values and customer ranges are established per sponsor's internal procedural specifications. | Example target values (mIU/mL): MCM1: 0.00, MCM2: 1.50, MCM3: 4.50, MCM4: 12.0, MCM5: 30.0, MCM6: 62.5, MCM7: 130, MCM8: 225. Assay Range: 0.3–200 mIU/mL. |
Traceability | Standardized against WHO 2nd International Standard for human FSH (IS 94/632). | ADVIA Centaur FSH = 0.91 (WHO) - 0.18 mIU/mL (r = 0.999). Assigned values for calibrators/MCMs are traceable to this standardization. |
ADVIA Centaur® FT4 Master Curve Material
Acceptance Criteria Category | Specific Acceptance Criteria | Reported Device Performance |
---|---|---|
Stability | ||
Real Time/Shelf Life (Unopened) | The dose recovery for MCM1 and the % dose recoveries for MCM2-7 met the sponsor's required acceptance criteria. | Acceptance criteria met up to the 7 months' time point, supporting a 6-month shelf-life claim (storage unopened at 2-8°C). Real-time studies are ongoing. |
In-Use Open Vial (Reconstituted) | The dose recovery for MCM1 and the % dose recoveries for MCM2-7 met the sponsor's required acceptance criteria. | Acceptance criteria met, supporting an open vial claim of 14 days (when properly stored at 2–8°C). |
On-Board Stability | The dose recovery for MCM1 and the % dose recoveries for MCM2-7 met the sponsor's required acceptance criteria. | Acceptance criteria met up to 5 hours, supporting an on-board stability claim for 4 hours. |
Value Assignment | The new MCM doses must fall within the final value assignment specification for FT4 MCMs. The mean MCM doses must fall within customer range specifications. MCM1 must measure at or below the FT4 assay sensitivity limit. | MCMs are value assigned using assigned reference calibrators and MCMs. Performance verification run (6 replicates per level) ensures mean MCM doses fall within customer range specifications. A nested testing run protocol is used for MCM2-7 value assignment (20 replicates in total). Implies acceptance criteria were met. |
Expected Values | Lot-specific assigned values and customer ranges are established per sponsor's internal procedural specifications. | Example target values (ng/dL): MCM1: 0.00, MCM2: 0.42, MCM3: 0.80, MCM4: 1.70, MCM5: 3.0, MCM6: 5.6, MCM7: 13.5. Assay Range: 0.1-12.0 ng/dL. |
Traceability | Standardized to an internal standard manufactured using USP (United States Pharmacopeia) material. | Assigned values for calibrators and MCMs are traceable to this standardization. |
ADVIA Centaur® T4 Master Curve Material
Acceptance Criteria Category | Specific Acceptance Criteria | Reported Device Performance |
---|---|---|
Stability | ||
Real Time/Shelf Life (Unopened) | The dose recovery for MCM1 and the % dose recoveries for MCM2-6 met the sponsor's required acceptance criteria. | Acceptance criteria met up to the 11 months' time point, supporting a 10-month shelf-life claim (storage unopened at 2-8°C). Real-time studies are ongoing. (No information on open vial or on-board stability for T4 MCM in this summary) |
Value Assignment | The new MCM doses must fall within the final value assignment specification for T4 MCMs. The mean MCM doses must fall within customer range specifications. MCM1 must measure at or below the T4 assay sensitivity limit. | MCMs are value assigned using assigned reference calibrators and MCMs. Performance verification run (6 replicates per level) ensures mean MCM doses fall within customer range specifications. A nested testing run protocol is used for MCM2-6 value assignment (20 replicates in total). MCM6 is diluted 1:4 before testing to meet reportable range. Implies acceptance criteria were met. |
Expected Values | Lot-specific assigned values and customer ranges are established per sponsor's internal procedural specifications. | Example target values (µg/dL): MCM1: 0.00, MCM2: 2.50, MCM3: 5.00, MCM4: 10.0, MCM5: 15.0, MCM6: 35.0. Assay Range: 0.3–30.0 µg/dL. |
Traceability | Standardized to an internal standard manufactured using USP (United States Pharmacopeia) material. | Assigned values for calibrators and MCMs are traceable to this standardization. |
ADVIA Centaur® T3 Master Curve Material
Acceptance Criteria Category | Specific Acceptance Criteria | Reported Device Performance |
---|---|---|
Stability | ||
Real Time/Shelf Life (Unopened) | The dose recovery for MCM1 and the % dose recoveries for MCM2-7 met the sponsor's required acceptance criteria. | Acceptance criteria met up to the 11 months' time point, supporting a 10-month shelf-life claim (storage unopened at 2-8°C). Real-time studies are ongoing. |
In-Use Open Vial (Reconstituted) | The dose recovery for MCM1 and the % dose recoveries for MCM2-7 met the sponsor's required acceptance criteria. | Acceptance criteria met up to the 22 days' time point, supporting an open vial claim of 21 days (when properly stored at 2-8°C). |
On-Board Stability | The dose recovery for MCM1 and the % dose recoveries for MCM2-7 met the sponsor's required acceptance criteria. | Acceptance criteria met up to 5 hours, supporting an on-board stability claim for 4 hours. |
Value Assignment | The new MCM doses must fall within the final value assignment specification for T3 MCMs. The mean MCM doses must fall within customer range specifications. MCM1 must measure at or below the T3 assay sensitivity limit. | MCMs are value assigned using assigned reference calibrators and MCMs. Performance verification run (6 replicates per level) ensures mean MCM doses fall within customer range specifications. A nested testing run protocol is used for MCM2-7 value assignment (20 replicates in total). Implies acceptance criteria were met. |
Expected Values | Lot-specific assigned values and customer ranges are established per sponsor's internal procedural specifications. | Example target values (ng/mL): MCM1: 0.00, MCM2: 0.42, MCM3: 0.69, MCM4: 1.11, MCM5: 1.65, MCM6: 3.87, MCM7: 7.00. Assay Range: 0.1-8 ng/mL. |
Traceability | Standardized to an internal standard manufactured using USP (United States Pharmacopeia) material. | Assigned values for calibrators and MCMs are traceable to this standardization. |
2. Sample size used for the test set and the data provenance (e.g. country of origin of the data, retrospective or prospective)
The document describes several non-clinical performance tests, primarily stability studies and value assignment. These are prospective tests conducted by the sponsor (Siemens Healthcare Diagnostics Inc.).
- Stability Studies (Test Set):
- Real Time/Shelf Life (Unopened): Each MCM (FSH, FT4, T4, T3) was stored unopened at 2-8°C and tested at T=0, 7 months, and 10 or 11 months. Ongoing studies were mentioned at further time points (e.g., 14, 18, 24, 25 months for FSH; 15, 19, 24, 30, 31 months for FT4, T4, T3). The comparison was made against -80°C reference MCMs. No specific number of replicate MCM vials tested at each time point is explicitly stated, other than 'test FSH MCMs were stored'.
- In-Use Open Vial (Reconstituted): Each MCM (FSH, FT4, T3) was reconstituted, pooled, aliquoted, and stored at 2-8°C. They were tested in 5 replicates per level at T=0, 7, 14, 21, 28, and 29 days (for FSH, T3) or T=0, 7, 14, 21, 28, and 29 days (for FT4). T4 MCM summary did not include open vial stability data details.
- On-Board Stability: Pooled aliquots of each MCM (FSH, FT4, T3) in sample cups were stored on the ADVIA Centaur system and measured at T=0, 2, 4, and 5 hours. T4 MCM summary did not include on-board stability data details.
- Value Assignment (Test Set):
- For each new MCM lot, MCM1 (analyte-free) was run in 5 replicates on two separate runs.
- Other MCM levels (MCM2-8 for FSH, MCM2-7 for FT4/T3, MCM2-6 for T4) were tested using a nested testing run protocol with alternating samples of reference and new MCM, totaling 20 replicates.
- A performance verification run consisted of 6 replicates of each MCM level.
- Data Provenance: The studies were conducted by Siemens Healthcare Diagnostics Inc., likely in the USA. The data is prospective, generated specifically for this 510(k) submission.
3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts
This type of in vitro diagnostic quality control material does not rely on "expert" interpretation in the same way as, for example, an imaging device. The "ground truth" for these materials is established through a process of:
- Traceability: Standardization to internationally recognized reference materials (e.g., WHO 2nd International Standard for human FSH) or internal standards traceable to official pharmacopeia (USP T4, T3 stock).
- Assigned Values: The values of the MCMs are assigned by the manufacturer based on these traceable standards and validated measurement procedures.
- Internal Protocols: The "sponsor's internal procedural specifications" and "qualified materials and measurement procedures" form the basis for establishing the expected values and ranges.
Therefore, there are no "experts" (like radiologists) establishing ground truth in terms of diagnostic interpretation from patient data. The ground truth is analytical and based on metrological traceability and rigorous laboratory procedures.
4. Adjudication method (e.g., 2+1, 3+1, none) for the test set
Adjudication methods like 2+1 or 3+1 (where multiple experts independently assess and then resolve discrepancies) are not applicable here. These methods are used in scenarios involving subjective expert interpretation, often for imaging or clinical diagnosis. For these quality control materials, "ground truth" and performance are determined through quantitative analytical measurements against established reference values and statistical methods to ensure measurements fall within specified limits.
5. If a multi-reader multi-case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance
MRMC studies are typically performed for diagnostic imaging devices where human readers (e.g., radiologists) interpret cases, sometimes with AI assistance. This document describes in vitro diagnostic quality control materials, not a diagnostic AI device that involves human interpretation of cases. Therefore, no MRMC comparative effectiveness study was performed, and thus no effect size for human reader improvement with AI assistance is mentioned.
6. If a standalone (i.e., algorithm only without human-in-the-loop performance) was done
Yes, the studies described are standalone in the sense that they evaluate the performance of the quality control materials themselves (stability, value assignment) within the ADVIA Centaur assay system, without direct human cognitive input being part of the 'device's' analytical function during testing. The "algorithm" here is the underlying immunoassay technology, and the MCM's performance is tested analytically.
7. The type of ground truth used (expert consensus, pathology, outcomes data, etc.)
The ground truth used for these quality control materials is analytical traceability to recognized international standards (WHO) or national pharmacopeia (USP) for the respective analytes. It also includes reliance on the sponsor's "qualified materials and measurement procedures" and internal procedural specifications for value assignment. This is an objective, quantitative ground truth, not derived from expert consensus, pathology, or outcomes data.
8. The sample size for the training set
The concept of a "training set" is relevant for machine learning algorithms. These devices are chemical/biological reagents designed as quality control materials for immunoassays, not AI algorithms. Therefore, there is no "training set" as understood in machine learning. The manufacturing processes and associated testing are quality control steps, not a machine learning training phase.
9. How the ground truth for the training set was established
As there is no "training set" in the machine learning sense for these devices, this question is not applicable. The establishment of ground truth for the performance evaluation (test set, as discussed in point 7) is through analytical traceability to standards.
Ask a specific question about this device
(34 days)
The ADVIA Centaur® IgE Master Curve Material is for in vitro diagnostic use in the verification of calibration and reportable range of the ADVIA Centaur Total IgE assay.
ADVIA Centaur® IgE Master Curve Material is an in vitro diagnostic product containing various levels of IgE spiked in lyophilized human plasma with sodium azide (0.1%) and preservatives. Each set contains seven levels (MCM1–7); with a reconstituted volume of 1.0 mL/vial per level. MCM1 contains no analyte. The MCMs assigned values are lot-specific of target values: 0.0, 12.5, 40.0, 270, 1000, 1700, and 3150 IU/mL.
This document describes the ADVIA Centaur® IgE Master Curve Material (MCM), a quality control material used for in vitro diagnostic verification of calibration and reportable range of the ADVIA Centaur Total IgE assay. It is not an AI/ML device, and therefore several of the requested sections (e.g., sample size for test/training sets, number/qualifications of experts, adjudication methods, MRMC studies, standalone algorithm performance, data provenance) are not applicable.
Here's a breakdown of the available information:
1. Table of Acceptance Criteria and Reported Device Performance
The device is a quality control material, not a diagnostic test with metrics like sensitivity or specificity. Its performance is measured by its stability and its ability to be correctly value-assigned.
Performance Metric | Acceptance Criteria (Sponsor's Required Acceptance Criteria) | Reported Device Performance |
---|---|---|
Real Time/Shelf Life Stability | MCM1 dose recovery ≤ 2.0 IU/mL; MCM2-7 % dose recovery met sponsor's required acceptance criteria. | Current testing meets the sponsor's acceptance criteria for the real-time stability study up to the 9 months' time point, supporting an 8-month shelf-life claim when stored unopened at 2-8°C. |
In-Use Open Vial (Reconstituted) Stability | MCM1 dose recovery |
Ask a specific question about this device
(29 days)
The ADVIA Centaur® Prolactin (PRL) Master Curve Material is for in vitro diagnostic use in the verification of calibration and reportable range of the ADVIA Centaur Prolactin assay.
The ADVIA Centaur® Cortisol (COR) Master Curve Material is for in vitro diagnostic use in the verification of calibration and reportable range of the ADVIA Centaur Cortisol assay.
ADVIA Centaur® Prolactin Master Curve Material is an in vitro diagnostic product containing various levels of prolactin spiked in lyophilized equine serum with sodium azide (0.1%) and preservatives including amphotericin B. Each set contains ten levels (MCM1–10); with a reconstituted volume of 1.0 mL per level. MCM1contains no analyte. The MCMs assigned values are lot-specific of target values: 0.00, 2.11, 4.61, 9.21, 26.0, 51.1, 82.9, 113, 161, and 218 ng/mL.
ADVIA Centaur® Cortisol Master Curve Materials is an in vitro diagnostic product containing various levels of cortisol in lyophilized human plasma with sodium azide. Each set contains seven lyophilized levels (MCM1-7); with a reconstituted volume of 1.0 mL each. MCM1 contains no analyte. The COR MCMs assigned values are lot-specific of target values: 0.00, 1.00, 2.00, 6.00, 12.0, 30.0, and 80.0 µg/dL.
The provided text describes the acceptance criteria and supporting studies for two Master Curve Materials (MCMs): ADVIA Centaur Prolactin (PRL) MCM and ADVIA Centaur Cortisol (COR) MCM. These materials are intended for in vitro diagnostic use in verifying the calibration and reportable range of their respective assays.
Here's a breakdown of the requested information:
ADVIA Centaur Prolactin (PRL) Master Curve Material
1. Table of acceptance criteria and reported device performance:
Acceptance Criteria Category | Specific Criteria | Reported Device Performance |
---|---|---|
Stability | ||
Real Time/Shelf Life (Unopened) | Dose recovery for MCM1 and % dose recovery for MCM2-10 met the requirements of the acceptance criteria and no adverse trends. | Met up to the 30 months' time point, supporting a shelf-life claim of 29 months when stored at 2-8°C. |
In-Use Open Vial (Reconstituted) | Dose recovery for MCM1 and the % dose recovery MCM2-10 met the requirements of the acceptance criteria. | Met to the 29 days' time point, supporting an open vial claim of 28 days when properly stored at 2-8°C. |
On-Board | Dose recovery for MCM1 and the % dose recovery for MCM2-10 met the requirements of the acceptance criteria. | Met up to 5 hours, supporting an on-board stability claim for 4 hours. |
Value Assignment | MCM1 measures at or below the PRL assay sensitivity limit. New MCM doses fall within the final value assignment specification for PRL MCMs. Mean MCM doses of the new MCM lot fall within the customer range specifications. | MCM1 target is 0.0 dose and is analyte-free. MCMs are manufactured using qualified materials and measurement procedures. New MCM doses are calculated based on the relationship between observed reference MCM dose and its assigned value using a two-point calibration. Performance verification runs ensure mean MCM doses fall within customer range specifications. (Specific quantitative results for individual lots are lot-specific as shown in Table 2, page 9). |
Expected Values | Lot-specific assigned values and lot-specific customer ranges established per % interval (MCM1: N/A, MCM2: 40%, MCM3-MCM9: 25%, MCM10: 20%). | Example lot-specific target and assigned values are provided, demonstrating adherence to the defined intervals (e.g., Table 2). The assay range is 0.3–200 ng/mL. |
Traceability | The ADVIA Centaur Prolactin assay is traceable to World Health Organization (WHO) 3rd IRP for Prolactin (84/500). Assigned values for calibrators and MCMs are traceable to this standardization. The PRL MCMs are manufactured using qualified materials and measurement procedures. | The PRL MCMs are traceable to WHO 3rd IRP for Prolactin (84/500) through internal material standardized against it. MCMs are manufactured using qualified materials and measurement procedures. |
2. Sample size used for the test set and the data provenance:
- Real Time/Shelf Life (unopened): Test PRL MCMs stored unopened. Tested at T=0, 12 months, and 30 months. The sample size for each time point is not explicitly stated in terms of number of individual units, but it's implied that multiple samples were tested to establish dose recovery.
- In-Use Open Vial (reconstituted): Reconstituted PRL MCMs, each level pooled, aliquotted, and stored at 2-8°C. Tested in 5 replicates per level at T=0, 7, 14, 21, 28, and 29 days. (10 levels * 5 replicates * 6 time points = 300 measurements total, minimum).
- On-Board Stability: Pooled aliquots of test PRL MCMs in sample cups. Measured at T=0, 2, 4, and 5 hours. Sample size not explicitly stated for number of individual units, but likely multiple measurements per time point.
- Value Assignment Test Set: For a new PRL MCM lot, MCM1 is run in 5 replicates on two separate runs. MCM2-MCM10 were tested on 20 replicates in total (one run and four sample cups run in 5 replicates). Performance verification run used 6 replicates of each MCM level.
- Data Provenance: The studies were conducted by Siemens Healthcare Diagnostics, Inc. The data is retrospective for the purpose of demonstrating the device's performance for this 510(k) submission. Country of origin not explicitly stated, but the manufacturer is based in the USA.
3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts:
Not applicable. These are in vitro diagnostic materials used for calibration verification, not for making clinical diagnoses based on subjective expert review. The "ground truth" for the MCMs is established by their formulation (analyte-free for MCM1, spiked levels for others) and traceability to recognized standards (WHO 3rd IRP for Prolactin 84/500) and internal reference materials.
4. Adjudication method for the test set:
Not applicable for this type of device and study. Performance is assessed against quantitative, pre-defined acceptance criteria, not through expert adjudication of results.
5. If a multi reader multi case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance:
Not applicable. This is an in vitro diagnostic (IVD) material, not an AI-powered diagnostic device, and therefore no MRMC study was performed.
6. If a standalone (i.e. algorithm only without human-in-the-loop performance) was done:
Not applicable. This is an IVD material, not an algorithm. Its performance is evaluated intrinsically through stability and value assignment studies on an automated analyzer (ADVIA Centaur system).
7. The type of ground truth used:
The ground truth for the PRL MCMs is primarily based on:
- Traceability to International Standards: Specifically, the World Health Organization (WHO) 3rd International Reference Preparation (IRP) for human Prolactin 84/500.
- Analytical Procedures: MCMs are manufactured using qualified materials and measurement procedures, and for MCMs 2-10, known concentrations of prolactin are spiked into a matrix. MCM1 is analyte-free basepool.
- Value Assignment: Reference calibrators are prepared using Prolactin stock traceable to the WHO standard. The MCMs are value assigned against these reference calibrators using a nested testing run protocol to account for system and run variation.
8. The sample size for the training set:
Not applicable. This is an IVD material, not an AI model that requires a training set.
9. How the ground truth for the training set was established:
Not applicable.
ADVIA Centaur Cortisol (COR) Master Curve Material
1. Table of acceptance criteria and reported device performance:
Acceptance Criteria Category | Specific Criteria | Reported Device Performance |
---|---|---|
Stability | ||
Real Time/Shelf Life (Unopened) | Dose recovery for MCM1 and % dose recovery for MCM2-7 met the requirements of the acceptance criteria and no adverse trends. | Met up to the 23 months' time point, supporting a shelf-life claim of 22 months when stored at 2-8°C. |
In-Use Open Vial (Reconstituted) | Dose recovery for MCM1 and % dose recovery for MCM2-7 met the requirements of the acceptance criteria. | Met to the 15 days' time point, supporting an open vial claim of 14 days when properly stored at 2-8°C. |
On-Board | Dose recovery for MCM1 and % dose recovery for MCM2-7 met the requirements of the acceptance criteria. | Met up to 5 hours, supporting an on-board stability claim for 4 hours. |
Value Assignment | MCM1 measures at or below the Cortisol assay sensitivity limit. New MCM doses fall within the final value assignment specification for COR MCMs. Mean MCM doses of the new MCM lot fall within the customer range specifications. | MCM1 target is 0.0 dose and is analyte-free. MCMs are manufactured using qualified materials and measurement procedures. New MCM doses are calculated based on the relationship between observed reference MCM dose and its assigned value using a two-point calibration. Performance verification runs ensure mean MCM doses fall within customer range specifications. (Specific quantitative results for individual lots are lot-specific as shown in Table 2, page 16). |
Expected Values | Lot-specific assigned values and lot-specific customer ranges established per % interval (MCM1: N/A, MCM2: 35%, MCM3-MCM6: 30%, MCM7: 20%). | Example lot-specific target and assigned values are provided, demonstrating adherence to the defined intervals (e.g., Table 2). The assay range is 0.20–75 µg/dL. |
Traceability | The ADVIA Centaur Cortisol assay is standardized using internal standards manufactured analytically which are traceable to gas chromatography-mass spectroscopy (GCMS). Assigned values for calibrators and MCMs are traceable to this standardization. The COR MCMs are manufactured using qualified materials and measurement procedures. | The COR MCMs are traceable to gas chromatography-mass spectroscopy (GCMS) through analytically prepared internal materials. MCMs are manufactured using qualified materials and measurement procedures. |
2. Sample size used for the test set and the data provenance:
- Real Time/Shelf Life (unopened): Test COR MCMs stored unopened. Tested at T=0, 12 months, 18 months, and 23 months. The sample size for each time point is not explicitly stated in terms of number of individual units, but it's implied that multiple samples were tested to establish dose recovery.
- In-Use Open Vial (reconstituted): Reconstituted COR MCMs, each level pooled, aliquotted, and stored at 2-8°C. Tested in 5 replicates per level at T=0, 2, 4, 7, 11, 14, and 15 days. (7 levels * 5 replicates * 7 time points = 245 measurements total, minimum).
- On-Board Stability: Pooled aliquots of test COR MCMs in sample cups. Measured at T=0, 2, 4, and 5 hours. Sample size not explicitly stated for number of individual units, but likely multiple measurements per time point.
- Value Assignment Test Set: For a new COR MCM lot, MCM1 is run in 5 replicates on two separate runs. MCM2-MCM7 were tested on 20 replicates in total (one run and four sample cups run in 5 replicates). Performance verification run used 6 replicates of each MCM level.
- Data Provenance: The studies were conducted by Siemens Healthcare Diagnostics, Inc. The data is retrospective for the purpose of demonstrating the device's performance for this 510(k) submission. Country of origin not explicitly stated, but the manufacturer is based in the USA.
3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts:
Not applicable. These are in vitro diagnostic materials used for calibration verification, not for making clinical diagnoses based on subjective expert review. The "ground truth" for the MCMs is established by their formulation (analyte-free for MCM1, spiked levels for others) and traceability to recognized standards (GCMS) and internal reference materials.
4. Adjudication method for the test set:
Not applicable for this type of device and study. Performance is assessed against quantitative, pre-defined acceptance criteria, not through expert adjudication of results.
5. If a multi reader multi case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance:
Not applicable. This is an in vitro diagnostic (IVD) material, not an AI-powered diagnostic device, and therefore no MRMC study was performed.
6. If a standalone (i.e. algorithm only without human-in-the-loop performance) was done:
Not applicable. This is an IVD material, not an algorithm. Its performance is evaluated intrinsically through stability and value assignment studies on an automated analyzer (ADVIA Centaur system).
7. The type of ground truth used:
The ground truth for the COR MCMs is primarily based on:
- Traceability to Reference Methods: Specifically, gas chromatography-mass spectroscopy (GCMS) through analytically prepared internal standards.
- Analytical Procedures: MCMs are manufactured using qualified materials and measurement procedures, and for MCMs 2-7, known concentrations of cortisol are spiked into a matrix. MCM1 is analyte-free basepool.
- Value Assignment: Reference calibrators are prepared using cortisol stock traceable to GCMS. The MCMs are value assigned against these reference calibrators using a nested testing run protocol to account for system and run variation.
8. The sample size for the training set:
Not applicable. This is an IVD material, not an AI model that requires a training set.
9. How the ground truth for the training set was established:
Not applicable.
Ask a specific question about this device
(28 days)
The ADVIA Centaur® C-peptide (CpS) Master Curve Material is for in vitro diagnostic use in the verification of calibration and reportable range of the ADVIA Centaur C-peptide assay.
The ADVIA Centaur® Insulin (IRI) Master Curve Material is for in vitro diagnostic use in the verification of calibration and reportable range of the ADVIA Centaur Insulin assay.
ADVIA Centaur® C-peptide Master Curve Material is an in vitro diagnostic product containing various levels of C-peptide spiked in citric acid buffer with casein and preservatives. Each set contains ten levels (MCM1–10); ready-to-use 1.0 mL per level. MCM1 contains no analyte. The MCMs assigned values are lot-specific of target values 0.0 0.14, 0.25, 0.55, 1.05, 2.05, 4.00, 8.00, 16.0, 32.5 ng/mL.
ADVIA Centaur® Insulin Master Curve Materials is an in vitro diagnostic product containing various levels of insulin in buffered saline with casein, potassium thiocyanate (3.89%), sodium azide (
The provided document describes the Siemens ADVIA Centaur C-peptide (CpS) Master Curve Material (MCM) and ADVIA Centaur Insulin (IRI) Master Curve Material (MCM). These devices are described as in vitro diagnostic products for the verification of calibration and reportable range of their respective assays. The document focuses on establishing substantial equivalence to predicate devices and describes relevant performance characteristics, primarily stability and value assignment.
Here's an analysis of the acceptance criteria and supporting studies based on the provided text:
Device Type: In vitro diagnostic Master Curve Material (MCM) - these are control materials used to verify the calibration and reportable range of an assay, not a diagnostic device that produces patient-specific results. Therefore, the questions related to clinical performance (e.g., diagnostic accuracy metrics like sensitivity, specificity, PPV, NPV), multi-reader multi-case studies, human reader improvement with AI, and specific ground truth types like pathology or outcomes data are not applicable in the context of this device and the provided documentation. The "performance" here refers to the stability and accurate value assignment of the control material itself.
1. Acceptance Criteria and Reported Device Performance
For ADVIA Centaur C-peptide (CpS) Master Curve Material (MCM):
Acceptance Criteria Category | Specific Acceptance Criteria | Reported Device Performance |
---|---|---|
Real Time/Shelf Life (Unopened) Stability | - MCM1 dose recovery: |
Ask a specific question about this device
(32 days)
The ADVIA Centaur® Vitamin B12 (VB12) Master Curve Material is for in the verification of calibration and reportable range of the ADVIA Centaur VB12 assay.
The ADVIA Centaur® Total hCG (ThCG) Master Curve Material is for in the verification of calibration and reportable range of the ADVIA Centaur ThCG assay.
The ADVIA Centaur® Testosterone (TSTO) Master Curve Material is for in the verification of calibration and reportable range of the ADVIA Centaur Testosterone assay.
ADVIA Centaur® Vitamin B12 Master Curve Material is an in vitro diagnostic product containing various levels of vitamin B12 in buffered human serum albumin with sodium azide (0.2%) and preservatives. Each set contains six levels (MCM1-6); with a fill volume of 1.0 mL per level. VB12 MCMs are ready-to-use liquid products. MCM1 contains no analyte. The MCMs assigned values are lot-specific of target values: 0.00, 100, 250, 500, 1000, and 2200 pg/mL.
ADVIA Centaur® ThCG Master Curve Materials is an in vitro diagnostic product containing various levels of ThCG in lyophilized equine serum with preservatives including amphotericin B. Each set contains ten lyophilized levels (MCM1-10); with a reconstituted volume of 1.0 mL each. MCM1 contains no analyte. The ThCG MCMs assigned values are lot specific of target values: 0.0, 5.00, 10.0, 25.0, 50.0, 100, 250, 500, 750, and 1400 mIU/mL.
ADVIA Centaur® TSTO Master Curve Materials is an in vitro diagnostic product containing various levels of testosterone spiked in lyophilized human plasma with sodium azide and preservatives. Each set contains seven lyophilized levels (MCM1-7); with a reconstituted volume of 1.0 mL each. MCMI contains no analyte. The TSTO MCMs assigned values are lot specific of target values 0.00, 50.0, 100, 500, 750, 1000, and 1600 ng/dL.
Acceptance Criteria and Study for ADVIA Centaur® VB12 Master Curve Material
The document describes three separate Master Curve Materials (MCMs): VB12, ThCG, and TSTO. This analysis focuses specifically on the ADVIA Centaur® Vitamin B12 (VB12) Master Curve Material.
1. Table of Acceptance Criteria and Reported Device Performance
The acceptance criteria for the ADVIA Centaur® VB12 MCMs primarily relate to their stability. The study demonstrated that the device met these criteria.
Acceptance Criteria Category | Specific Criteria | Reported Device Performance |
---|---|---|
Real Time/Shelf Life (Unopened) | - MCM1: Dose recovery ≤ 45 pg/mL |
- MCM2: % dose recovery within 75% to 125%
- MCM3-6: % dose recovery within 85% to 115%
(All calculated back to Day 0 and/or no adverse trends) | Met acceptance criteria up to the 15 months' time point, supporting a shelf-life claim of 14 months. Unopened storage shelf-life is indicated by the expiration date on the vial label. |
| On-Board Stability | - MCM1: Dose recovery ≤ 45 pg/mL - MCM2: % dose recovery within 75% to 125%
- MCM3-6: % dose recovery within 85% to 115%
(All calculated to T=0) | Met acceptance criteria up to 5 hours, supporting an on-board stability claim of 4 hours. |
2. Sample Size Used for the Test Set and Data Provenance
- Test Set Description: The test set for stability studies consisted of "Test VB12 MCMs" which were individual levels of the Master Curve Material (MCM1-6).
- Sample Size:
- Real Time/Shelf Life: Not explicitly stated as a number of individual samples, but likely involved multiple aliquots of each MCM level (MCM1-6) stored and tested at T=0, 6 months, 12 months, and 15 months. The exact number of replicates per time point is not specified but implied to be sufficient for a robust assessment.
- On-Board Stability: Not explicitly stated as a number of individual samples, but "Pooled aliquots of test VB12 MCMs in sample cups" were used and measured at T=0, 2, 4, and 5 hours. The exact number of replicates per time point is not specified.
- Data Provenance: Not explicitly stated in the provided text (e.g., country of origin). The studies appear to be prospective as they involved controlled storage and testing over defined time intervals to assess stability.
3. Number of Experts Used to Establish the Ground Truth for the Test Set and Qualifications of Those Experts
This device is a Quality Control (QC) material, not a diagnostic device requiring human interpretation of clinical images or data. Therefore, the concept of "experts" establishing ground truth in the traditional sense (e.g., radiologists) does not apply. The "ground truth" for the performance of this QC material is established by analytical testing against defined reference materials and specifications.
4. Adjudication Method for the Test Set
The concept of an adjudication method (like 2+1, 3+1) is not applicable here. The performance is assessed by comparing dose recovery results to pre-defined numerical acceptance criteria for stability.
5. If a Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study Was Done
No, an MRMC comparative effectiveness study was not done. This type of study is relevant for diagnostic devices where human readers interpret clinical cases, often with and without AI assistance. This device is a quality control material for an in-vitro diagnostic assay.
6. If a Standalone (i.e., algorithm only without human-in-the-loop performance) Was Done
The performance study (stability) is inherently "standalone" in the sense that it evaluates the material's integrity over time without human-in-the-loop performance, as it's a quality control product. The assay itself for which this MCM is used is automated.
7. The Type of Ground Truth Used
The ground truth for the VB12 MCM is established through:
- Traceability to a recognized standard: The assigned reference calibrators are prepared using USP (United States Pharmacopeia) VB12 stock and are traceable to USP internal material.
- Defined analytical specifications: The dose recovery acceptance criteria (e.g., ≤ 45 pg/mL, % recovery ranges) serve as the "ground truth" for determining if the material remains stable and performs as expected.
- Manufacturing procedures: MCMs are manufactured using "qualified materials and measurement procedures."
8. The Sample Size for the Training Set
This device is a physical Master Curve Material (MCM), not a machine learning model that requires a "training set" in the conventional sense. The "value assignment" process could be considered analogous to establishing its baseline characteristics.
For value assignment of a new VB12 MCM lot:
- MCM1: Run in 5 replicates on two separate runs using one reagent kit lot.
- MCM2-MCM6: Tested on 20 replicates in total, comprised of one run and four sample cups run in 5 replicates on one system and one reagent kit lot.
9. How the Ground Truth for the Training Set Was Established
As noted above, there isn't a "training set" in the machine learning context. However, the process by which the "ground truth" or assigned values for the MCMs are established is described as follows:
- Reference Calibrators: The ADVIA Centaur VB12 MCMs are value assigned using assigned reference calibrators. These calibrators are prepared using USP (United States Pharmacopeia) VB12 stock and are traceable to USP internal material.
- Value Assignment Process:
- MCM1's target is 0.0 dose, and its quality control specifications ensure it measures at or below the assay sensitivity limit.
- A nested testing run protocol is used for MCM2-MCM6, involving running alternating samples of the reference and new MCM level in the same run to remove system and run variation.
- Resulting MCM dose values are generated using a two-point calibration.
- The new MCM dose is calculated based on the relationship between the observed reference MCM dose and its assigned value.
- Performance Verification: A performance verification run with 6 replicates of each MCM level (using one instrument, one reagent kit lot, and Bio-Rad controls) is conducted. The mean MCM doses of the new lot must fall within customer range specifications.
Ask a specific question about this device
(35 days)
The ADVIA Centaur® TnI-Ultra® Master Curve Material is for in vitro diagnostic use in the verification of calibration and reportable range of the ADVIA Centaur TnI-Ultra assay.
The ADVIA Centaur® Digoxin Master Curve Material is for in vitro diagnostic use in the verification of calibration and reportable range of the ADVIA Centaur Digoxin assay.
ADVIA Centaur® TnI-Ultra® Master Curve Material is an in vitro diagnostic product containing various levels of bovine cardiac troponin I in a goat serum matrix with preservatives. Each set contains five lyophilized levels (MCM1-5); with a reconstituted volume of 1.0 ml each. MCM1 contains no analyte. The Tnl-Ultra MCMs assigned values are lot-specific of target values 0.00, 1.00, 3.50, 14.0 and 40.0 ng/mL.
ADVIA Centaur® Digoxin Master Curve Materials is an in vitro diagnostic product containing various levels of digoxin in defibrinated human plasma with sodium azide (0.1% after reconstitution) and preservatives. Each set contains six lyophilized levels (MCM1-6); with a reconstituted volume of 1.0 mL each. MCM1 contains no analyte. The Digoxin MCMs assigned values are lot specific of target values 0.0, 0.50, 1.00, 2.00, 3.00, 5.50 ng/mL.
The provided text describes two separate devices: ADVIA Centaur® TnI-Ultra® Master Curve Material (MCM) and ADVIA Centaur® Digoxin Master Curve Material (MCM). Both are quality control materials. I will detail the acceptance criteria and study information for each device independently.
ADVIA Centaur® TnI-Ultra® Master Curve Material (MCM)
1. Table of Acceptance Criteria and Reported Device Performance
Study Type | Acceptance Criteria | Reported Device Performance (Supports Claims) |
---|---|---|
Stability: Real Time/Shelf Life (Unopened) | - MCM1: Dose recovery ≤ 0.02 dose |
- MCM2-5: % dose recovery within 85% to 115% calculated to Day 0
- No adverse trends | Acceptance criteria were met up to the 10 months time point, supporting a shelf-life claim of 9 months. |
| Stability: In Use (Open Vial) @ 2-8°C (Reconstituted) | - MCM1: Dose recovery ≤ 0.02 dose (versus freshly reconstituted -80°C stored MCM1 average dose) - MCM2-5: % dose recovery within 85% to 115% (versus freshly reconstituted -80°C stored MCM2-5 average dose) | Acceptance criteria were met up to the 9 hour time point, supporting an open vial claim of 8 hours when stored at 2-8°C. |
| Stability: In Use (Open Vial) @ -20°C (Reconstituted) | - MCM1: Dose recovery ≤ 0.02 dose (versus freshly reconstituted -80°C stored MCM1 average dose) - MCM2-5: % dose recovery within 85% to 115% (versus freshly reconstituted -80°C stored MCM2-5 average dose) | Acceptance criteria were met up to the 63 days time point, supporting an open vial (reconstituted) claim stored at -20°C for 60 days. |
| Stability: On-Board | - MCM1: Dose recovery
Ask a specific question about this device
The ADVIA® Chemistry Myoglobin assay is for in vitro diagnostic use in the quantitative measurement of myoglobin in human serum or plasma on the ADVIA® Chemistry systems. Measurement of myoglobin aids in the rapid diagnosis of heart or renal disease.
The ADVIA Chemistry Myoglobin calibrator is for in vitro diagnostic use in the calibration of ADVIA® Chemistry system for Myoglobin assay.
The Myoglobin reagents are ready-to-use liquid reagents packaged for use on the automated ADVIA 1650 Chemistry system. They are supplied as a 100 tests/wedge, 2 wedges/kit. ADVIA Chemistry Myoglobin calibrator is a single analyte, human serum based product containing myoglobin derived from human heart source. The kit consists of 1 vial each of 4 calibrator levels which are lyophilized. The target concentrations of these calibrators are 50, 100, 200, and 720 ng/mL. The volume per vial (after reconstitution with deionized water) is 1.0 mL. Deionized water is recommended to be used as a zero calibrator.
Here's a breakdown of the acceptance criteria and study information based on the provided 510(k) summary:
1. Table of Acceptance Criteria and Reported Device Performance:
The document describes several performance characteristics and the results obtained for the ADVIA® 1650 Chemistry Myoglobin Assay. Since this is a submission for substantial equivalence to a predicate device, the "acceptance criteria" are implicitly the performance levels of the predicate device or generally accepted clinical laboratory standards as guided by CLSI documents. The reported performance of the new device is compared to these.
Performance Characteristic | Acceptance Criteria (Implicit/Guidance) | Reported Device Performance (ADVIA® 1650 Chemistry Myoglobin Assay) |
---|---|---|
Precision | As per CLSI EP05-A2 guidance | Within-run SD/CV: 0.70-4.22 SD, 0.5-0.8% CV (depending on sample/concentration) |
Total SD/CV: 1.41-10.23 SD, 1.8-6.2% CV (depending on sample/concentration) | ||
Linearity/Assay Reportable Range | Linear range typically defined by predicate device or clinical needs | Linear/measuring range: 22 to 680 ng/mL |
Limit of Blank (LoB) | As per CLSI EP17-A guidance | 12 ng/mL |
Limit of Detection (LoD) | As per CLSI EP17-A guidance | 21 ng/mL |
Limit of Quantitation (LoQ) | As per CLSI EP17-A guidance | 22 ng/mL |
Method Comparison (Serum) | Good correlation with predicate device (ADVIA Centaur Myoglobin assay) | Correlation coefficient: 0.99 |
Slope: 0.96 (95% CI: 0.95-0.98) | ||
Intercept: 12.5 ng/mL (95% CI: 8.3-16.7) | ||
Range tested: 19.9 - 684.0 ng/mL | ||
Matrix Comparison (Plasma) | Good correlation with predicate device (ADVIA Centaur Myoglobin assay) | Correlation coefficient: 0.99 |
Slope: 0.98 (95% CI: 0.96-1.00) | ||
Intercept: 14.1 ng/mL (95% CI: 8.1-20.1) | ||
Range tested: 18.9 - 624.1 ng/mL | ||
Analytical Specificity (Interference) |
Ask a specific question about this device
(195 days)
The B12 Flex® reagent cartridge is an in vitro diagnostic test for the quantitative measurement of Vitamin B12 in human serum and plasma on the Dimension Vista® system. Measurements obtained by this device are used in the diagnosis and treatment of gastrointestinal malabsorption.
The FOL Flex® reagent cartridge is an in vitro diagnostic test for the quantitative measurement of folate in human serum and plasma on the Dimension Vista® system. Measurements obtained by this device are used in the diagnosis and treatment of megaloblastic anemia.
The LOCI 4 Calibrator is an in vitro diagnostic product for the calibration of Ferritin (FERR), Vitamin B12 (B12), and Folate (FOL) methods on the Dimension Vista® system.
B12: The Dimension Vista® Vitamin B12 method is a homogeneous, competitive chemiluminescent immunoassay based on LOCTM technology. LOCT™ reagents include two synthetic bead reagents and biotinylated intrinsic factor (IF). The first bead reagent (Chemibeads) is coated with a B12 derivative and contains a chemiluminescent dye. The second bead reagent (Sensibeads) is coated with streptavidin and contains photosensitive dye. The patient sample is pretreated with NaOH to release the serum B12 from its carrier proteins. Potassium cyanide (KCN) is added to convert all the forms of B12 into a single, cyanocobalamin form, and dicyanocobinamide is added to keep the B12 from rebinding with the carrier proteins. After the sample pretreatment, the biotinylated IF and Chemibead reagents are added sequentially to the reaction vessel. Vitamin B12 from the sample competes with the B12-Chemibead for a limited amount of biotinylated IF. Sensibeads are then added and bind to the biotin to form bead pair immunocomplexes. Illumination of the complex at 680 nm generates singlet oxygen from the Sensibeads which diffuses to the Chemibeads triggering a chemiluminescent reaction. The resulting signal is measured at 612 nm and is an inverse function of the concentration of vitamin B12 in the sample.
FOL: The Dimension Vista® Folate method is a homogenous, competitive chemiluminescent immunoassay based on LOCT™ technology. LOCT™ reagents include two synthetic bead reagents and labeled folate binding protein (FBP). The first bead reagent (Chemibeads) is coated with a folic acid derivative and contains a chemiluminescent dye. The second bead reagent (Sensibeads) is coated with streptavidin and contains photosensitive dye. Before the immunological portion of the reaction is initiated, the patient sample is pretreated with NaOH and DTT to release serum folate from endogenous folate binding protein and to maintain 5-methyl tetrahydrofolate in its reduced form. After the sample pretreatment, Chemibeads and labeled folate binding reagent are added sequentially to the reaction vessel. Folate from the patient sample competes with the folate-Chemibead for a limited amount of labeled FBP. Sensibeads are then added and bind to the biotinylated portion of the labeled FBP to form bead pair immunocomplexes. Illumination of the complex by light at 680 nm generates singlet oxygen from the Sensibeads which diffuses to the Chemibeads triggering a chemiluminescent reaction. The resulting signal is measured at 612 nm and is an inverse function of the concentration of folate in the sample.
Calibrator: The Dimension Vista® LOCI 4 Calibrator is a five level, liquid calibrator. It is packaged as a kit of 10 vials, two vials each of five levels. The product matrix is 6% bovine serum albumin with buffer, stabilizer and preservatives. Level A is zero. Levels B through E contain Ferritin, Vitamin B12, and Folate at the following target concentrations: Level A: Ferritin 0 ng/mL, B12 0 pg/mL, Folate 0.0 ng/mL; Level B: Ferritin 26 ng/mL, B12 200 pg/mL, Folate 2.5 ng/mL; Level C: Ferritin 210 ng/mL, B12 500 pg/mL, Folate 5.0 ng/mL; Level D: Ferritin 1050 ng/mL, B12 1000 pg/mL, Folate 10.0 ng/mL; Level E: Ferritin 2000 ng/mL, B12 2100 pg/mL, Folate 21.0 ng/mL. Values are assigned to new lots from a masterpool that is referenced to the WHO standard for FERR, 3 14 IS 94/572 and United States Pharmacopoeia materials for B12 and Folate.
This document describes the regulatory submission for three in-vitro diagnostic products: Dimension Vista® Vitamin B12 Flex® reagent cartridge (B12), Dimension Vista® Folate Flex® reagent cartridge (FOL), and Dimension Vista® LOCI 4 Calibrator. The submission aims to demonstrate substantial equivalence to previously cleared predicate devices.
1. Table of Acceptance Criteria and Reported Device Performance
For the Dimension Vista® B12 and FOL Flex® reagent cartridge assays, the acceptance criteria are implicitly based on demonstrating comparable performance (correlation, slope, and intercept) to their respective predicate devices. The reported performance is based on a split-sample comparison study.
Device/Assay | Acceptance Criteria (Implied by Predicate Comparison) | Reported Device Performance (vs. Predicate) |
---|---|---|
B12 Flex® reagent cartridge | Performance comparable to VB12 for ADVIA Centaur® System (similar correlation, slope, and intercept) | Slope: 0.93 |
Intercept: -14.4 pg/mL | ||
Correlation Coefficient (r): 0.98 | ||
FOL Flex® reagent cartridge | Performance comparable to FOL for ADVIA Centaur® System (similar correlation, slope, and intercept) | Slope: 1.02 |
Intercept: -0.07 ng/mL | ||
Correlation Coefficient (r): 0.96 | ||
LOCI 4 Calibrator | Calibrates Ferritin, Vitamin B12, and Folate methods on the Dimension Vista® system and is traceable to international standards (WHO, USP). | Traceable to WHO Standard for ferritin 3rd IS 94/572, and USP material for B12 and Folate. |
2. Sample Size Used for the Test Set and Data Provenance
The test set consisted of clinical patient samples.
- B12: 124 clinical patient samples
- FOL: 110 clinical patient samples
The data provenance is not explicitly stated in terms of country of origin but is referred to as "clinical patient samples," implying retrospective. The study type is a "split sample comparison" study, which means portions of the same patient sample were tested on both the new device and the predicate device.
3. Number of Experts Used to Establish the Ground Truth for the Test Set and Qualifications of Those Experts
This information is not provided in the document. For in-vitro diagnostic comparative studies like this, the "ground truth" for individual patient samples is usually established by the predicate device's measurement, which is considered the established method. There is no mention of independent expert review of results or a separate ground truth determination method by experts.
4. Adjudication Method for the Test Set
This information is not applicable/provided as the study design is a direct comparison to a predicate device, not a classification task requiring adjudication of expert opinions.
5. If a Multi Reader Multi Case (MRMC) Comparative Effectiveness Study was Done, If So, What was the Effect Size of How Much Human Readers Improve with AI vs without AI Assistance
This information is not applicable. The device is an in-vitro diagnostic assay for measuring biomarkers (Vitamin B12 and Folate) and a calibrator. It is not an imaging or diagnostic aid that would involve human "readers" or AI assistance in interpretation.
6. If a Standalone (i.e. algorithm only without human-in-the-loop performance) was Done
The performance data presented is for the standalone performance of the Dimension Vista® B12 and FOL Flex® reagent cartridge assays, as they are fully automated in-vitro diagnostic tests. There is no human interpretation component in the measurement itself, only in the clinical application of the results.
7. The Type of Ground Truth Used
The ground truth for the performance study (comparison to predicate) was established by the measurements obtained from the legally marketed predicate devices (VB12 and FOL assays on the ADVIA Centaur® System). This is a common approach for demonstrating substantial equivalence for in-vitro diagnostic devices.
8. The Sample Size for the Training Set
This information is not provided. As an in-vitro diagnostic reagent and calibrator kit, these devices do not typically have an "algorithm" in the sense of machine learning that requires a separate training set. Their development involves R&D and validation steps, but not a distinct "training set" like an AI product would.
9. How the Ground Truth for the Training Set Was Established
This information is not provided and is generally not applicable in the context of these types of IVD reagent kits and calibrators. The development and manufacturing of these products involve rigorous quality control and calibration processes, often referenced to international standards, but not a "ground truth for a training set" in the common AI/machine learning sense.
Ask a specific question about this device
Page 1 of 1